Reducing Activities: company scaling back some business operations while continuing others
Stay Scaling BackReducing Activities: company scaling back some business operations while continuing others
Stay Scaling BackDanish diabetes care giant Novo Nordisk has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year.
Suspend further marketing and clinical investment; pause new clinical trials and active enrollment but increased revenue in Russia in 2022 vs 2021. Danish diabetes care giant Novo Nordisk (NOV: N) has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of year 2024. Revenue decreased in 2024 vs 2023 by more than -10%.